• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8/12/24 4:24:10 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELTX alert in real time by email
    false000160148500016014852024-08-122024-08-12

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): August 12, 2024
     
    Elicio Therapeutics, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
     
    001-39990
     
    11-3430072
    (State or other jurisdiction of incorporation)
     
    (Commission File Number)
     
    (I.R.S. Employer Identification No.)
     
    451 D Street, 5th Floor
    Boston, Massachusetts 02210
    (Address of principal executive offices, including zip code)
     
    (857) 209-0050
    (Registrant’s telephone number, including area code)
     
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trade
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.01 par value per share
     
    ELTX
     
    The Nasdaq Global Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
     
    Emerging growth company ☒
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 1.01. Entry into a Material Definitive Agreement.
     
    On August 12, 2024, Elicio Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026 (the “Convertible Note”) in the principal amount of $20.0 million (the “Note Financing”).  The purchaser of the Convertible Note is GKCC, LLC, an entity controlled by a member of the board of directors of the Company (the “Purchaser”). The Convertible Note was sold in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Company estimates that the net proceeds from the sale of the Convertible Note, after deducting offering expenses, will be approximately $19.7 million. The Company intends to use the net proceeds from the Note Financing for working capital and general corporate purposes.

    JonesTrading Institutional Services LLC served as financial advisor for the Note Financing.

    The Convertible Note will be a senior, secured obligation of the Company and its subsidiaries, and interest will accrue and be payable quarterly in cash on the principal amount equal to 3% per annum, with an initial interest payment date of June 30, 2025. The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. The Convertible Note is secured by a (i) first priority lien on substantially all assets of the Company and its subsidiaries, pursuant to the Security Agreement (as defined below) and (i) first priority lien on intellectual property of the Company, as further described in and pursuant to the IP Security Agreement (as defined below).
     
    The Convertible Note will be convertible into shares of the Company’s common stock, $0.01 par value per share (“Common Stock”), in whole or in part, at the option of the Purchaser at any time, based on an initial conversion price of $5.81 (the “Conversion Price”) per share of Common Stock, subject to adjustment in certain circumstances; provided that the Company shall not effect any conversion under the Convertible Note and the Purchaser thereof shall not have any right to convert any portion of the Convertible Note until the Company’s stockholders shall have provided all approvals as may be required by the applicable rules and regulations of The Nasdaq Stock Market, LLC (“Stockholder Approval”).

    If at any time from and after the date of the Securities Purchase Agreement and for so long as the closing price of the Common Stock on Nasdaq equals or exceeds 135% of the Conversion Price for 20 trading days in a 30 trading day period, then the Company has the right to require the Purchaser to convert all or any portion of the Convertible Note, including any accrued but unpaid interest into shares of Common Stock, as further described in the Convertible Note; provided that the Company shall not effect any such conversion under the Convertible Note until the Company obtains Stockholder Approval.
     
    The Convertible Note contains customary terms and covenants and customary events of default (an “Event of Default”). Upon the occurrence of any Event of Default, at the Purchaser’s election, the outstanding principal amount of the Convertible Note, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become immediately due and payable. After the occurrence of any Event of Default that results in the eventual acceleration of the Convertible Note, the interest rate on the Convertible Note shall accrue at an interest rate equal to 18% per annum (with a credit for any “unused” guaranteed interest).
     

    Pursuant to the Securities Purchase Agreement, the Company is obligated, among other things, to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) by November 15, 2024 for purposes of registering the shares of Common Stock issuable upon conversion of the Convertible Note for resale by the Purchaser, and to use its commercially reasonable efforts to have the registration statement declared effective no later than 30 days after filing such registration statement with the SEC, or in the event the SEC reviews and has written comments to the registration statement, within 90 days following the receipt of such written comments. The Securities Purchase Agreement contains customary terms and conditions for a transaction of this type, including certain customary indemnification rights and certain customary cash penalties on the Company for its failure to satisfy specified filing and effectiveness time periods.

    The Securities Purchase Agreement also contains certain affirmative and negative covenants (including, without limitation, restrictions on the Company’s ability to incur indebtedness, permit liens, make dividends or certain debt payments or consummate certain affiliate transactions) and customary representations and warranties of the Company and the Purchaser, indemnification obligations of the parties, termination provisions, and other obligations and rights of the parties.
     
    On August 12, 2024, in connection with the issuance of the Convertible Note, the Company also entered into a security agreement (the “Security Agreement”) and an intellectual property security agreement (the “IP Security Agreement”), each with the Purchaser, pursuant to which the Company granted the Purchaser a continuing security interest in certain collateral to secure the full and prompt payment, performance and observance of all present and future indebtedness, obligations, liabilities and agreements of any kind of the Company to the Purchaser arising under or in connection with the Convertible Note. On August 12, 2024, the Company’s subsidiaries (the “Guarantors”) also entered into a subsidiary guarantee (the “Subsidiary Guarantee”) with the Purchaser, pursuant to which the Guarantors have guaranteed to the Purchaser the prompt and complete payment and performance when due of the obligations under the Securities Purchase Agreement.
     
    The foregoing descriptions of the Convertible Note, the Securities Purchase Agreement, the Security Agreement, the IP Security Agreement and the Subsidiary Guarantee are only summaries of the material terms thereof, do not purport to be complete and are qualified in their entirety by reference to the full text of the form of the Convertible Note, the Securities Purchase Agreement, the Security Agreement, the IP Security Agreement and the Subsidiary Guarantee, which are filed as Exhibits 4.1, 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
     
    The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.

    Item 3.02. Unregistered Sales of Equity Securities.

    The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of the Purchaser in the Securities Purchase Agreement, the Convertible Note was sold in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. Neither the Convertible Note nor the Common Stock issuable on conversion thereof have been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy Convertible Notes, shares of Common Stock or other securities of the Company.

    Item 8.01. Other Events.
     
    On August 12, 2024, the Company issued a press release related to the Convertible Note. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
      

    Item 9.01. Financial Statements and Exhibits.
     
    (d) Exhibits
    Exhibit
    No.
     
    Description
     
     
     
    4.1
     
    Form of Senior Secured Convertible Promissory Note due February 15, 2026.
     
     
     
    10.1
     
    Securities Purchase Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC*
         
    10.2
     
    Security Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC*
     
     
     
    10.3
     
    IP Security Agreement, dated August 12, 2024, by and between the Company and GKCC, LLC*
     
     
     
    10.4
     
    Subsidiary Guarantee, dated August 12, 2024, among Elicio Operating Company, Inc., Elicio Securities Corp. and GKCC, LLC*
         
    99.1
     
    Press Release dated August 12, 2024.
     
     
     
    104
     
    Cover Page Interactive Data File (embedded within the inline XBRL document).
     
    *Certain exhibits and schedules have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request.


    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Elicio Therapeutics, Inc.
     
     
     
    Date: August 12, 2024
    By: 
    /s/ Robert Connelly
     
     
    Robert Connelly
     
     
    President and Chief Executive Officer
    (Principal Executive Officer)
     
     

    Get the next $ELTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elicio Therapeutics Reports Inducement Grants

    BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on February 17, 2026, Elicio granted an aggregate of 30,300 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. The grant provides for

    2/18/26 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Inducement Grants

    BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. Each grant provides f

    1/16/26 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Inducement Grants

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. Each grant provid

    12/16/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President and Director Connelly Robert was granted 73,600 shares, increasing direct ownership by 157% to 120,570 units (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/3/26 4:42:10 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Shah Preetam was granted 24,000 shares (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/3/26 4:40:15 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Demuth Peter was granted 20,800 shares, increasing direct ownership by 2,799% to 21,543 units (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/3/26 4:38:38 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    SEC Filings

    View All

    SEC Form EFFECT filed by Elicio Therapeutics Inc.

    EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)

    12/4/25 12:15:21 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Elicio Therapeutics Inc.

    S-3 - Elicio Therapeutics, Inc. (0001601485) (Filer)

    11/13/25 5:01:43 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Elicio Therapeutics Inc.

    10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

    11/13/25 4:08:50 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    8/14/24 5:01:49 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Elicio Therapeutics Inc.

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    7/2/24 4:39:47 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Elicio Therapeutics Inc. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    4/10/24 4:01:50 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELTX
    Leadership Updates

    Live Leadership Updates

    View All

    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

    BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

    11/19/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

    BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies. "We are pleased to welcome Preetam to Elicio's executive team," said Robert Connelly, Ph.D., Preside

    3/24/25 7:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

    BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company's product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. "Megan and Thian are joining us at an exc

    8/28/23 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care